Roche says it will not relinquish control over access to clinical trial dataBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f1374 (Published 28 February 2013) Cite this as: BMJ 2013;346:f1374
- Zosia Kmietowicz
Campaigners for full transparency of all clinical trial data have responded with incredulity to a statement from the drug company Roche saying that it would continue to hold back certain information and results from research into its drugs.
Tracey Brown, director of the charity Sense About Science, said that the company was “on another planet.”
In January Brown helped to set up the AllTrials campaign (www.alltrials.net), together with the BMJ and others, for all clinical trials to be registered and reported in full.1
So far the campaign has collected 37 889 signatures for its public petition to put pressure on researchers, funding bodies, and institutions to take action on the issue. And more than 180 organisations have signed up to the initiative, including the UK National Institute for Health and Clinical Excellence, the Wellcome Trust, the UK Medical Research Council and medical royal colleges, the drug company GlaxoSmithKline, and more than 90 patient groups.2
Researchers from the Cochrane Collaboration have been waiting for …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial